177 related articles for article (PubMed ID: 32399358)
1. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
Rai M; Go M
Cureus; 2020 Apr; 12(4):e7625. PubMed ID: 32399358
[TBL] [Abstract][Full Text] [Related]
2. Refractory hypotension due to Nivolumab-induced adrenal insufficiency.
Tsukizawa Y; Kondo K; Ichiba T; Naito H; Mizuki K; Masuda K
Nagoya J Med Sci; 2018 May; 80(2):285-288. PubMed ID: 29915446
[TBL] [Abstract][Full Text] [Related]
3. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
7. Case of nivolumab-induced delayed adrenal insufficiency during the treatment of renal cell carcinoma.
Yonezawa R; Takata E; Yamadera S; Sunaga T
J Oncol Pharm Pract; 2023 Mar; ():10781552231163294. PubMed ID: 36987710
[TBL] [Abstract][Full Text] [Related]
8. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
[TBL] [Abstract][Full Text] [Related]
9. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event.
Deligiorgi MV; Trafalis DT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107050. PubMed ID: 33069924
[TBL] [Abstract][Full Text] [Related]
10. A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab.
Galliazzo S; Morando F; Sartorato P; Bortolin M; De Menis E
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):363-366. PubMed ID: 34238203
[TBL] [Abstract][Full Text] [Related]
11. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
12. Hyponatraemia secondary to nivolumab-induced primary adrenal failure.
Trainer H; Hulse P; Higham CE; Trainer P; Lorigan P
Endocrinol Diabetes Metab Case Rep; 2016; 2016():. PubMed ID: 27857838
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
[TBL] [Abstract][Full Text] [Related]
14. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.
Tanaka S; Kushimoto M; Nishizawa T; Takubo M; Mitsuke K; Ikeda J; Fujishiro M; Ogawa K; Tsujino I; Suzuki Y; Abe M
Clin Diabetes Endocrinol; 2020; 6():1. PubMed ID: 31921440
[TBL] [Abstract][Full Text] [Related]
15. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Fujimura S; Taguchi A; Shoji K
Auris Nasus Larynx; 2020 Apr; 47(2):309-313. PubMed ID: 31235078
[TBL] [Abstract][Full Text] [Related]
16. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
18. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
19. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
20. Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy.
Ramani A; Maloney T; Mills B; Mazharuddin S; Mennel RG
Proc (Bayl Univ Med Cent); 2020 Apr; 33(2):251-253. PubMed ID: 32313477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
